Why Lumakras Costs $13,000.00 Per Claim
Lumakras (Sotorasib) is used to treat cancer. According to CMS Medicare Part D spending data, the program spent $234.0M on this drug, covering 2,100 beneficiaries across 18,000 claims.
A generic version of this drug is available, which means lower-cost alternatives exist. Patients should ask their pharmacist about generic Sotorasib or talk to their doctor about therapeutic alternatives that may cost less.
Spending on Lumakras increased by +28.4% year-over-year, driven by increased utilization among Medicare beneficiaries.
Price Breakdown
Drug Details
Frequently Asked Questions
Lumakras (Sotorasib) costs an average of $13,000.00 per claim based on Medicare Part D data. The estimated annual cost per patient is $111,429.00. Actual out-of-pocket costs depend on your insurance plan and pharmacy.
Lumakras averages $13,000.00 per Medicare Part D claim — roughly equivalent to a 30-day supply for most patients on standard dosing. Without insurance, expect higher cash-pay prices unless you use a discount program (GoodRx, SingleCare, manufacturer copay assistance). With Medicare or commercial insurance, your out-of-pocket cost depends on your plan's formulary tier and deductible status.
A typical 30-day supply of Lumakras reflects in our Medicare Part D average of $13,000.00 per claim. Switching to generic Sotorasib typically reduces cost by 80-95%. Cash-pay prices vary by pharmacy — comparison shopping (or using GoodRx coupons) often saves 20-50% off the listed price.
Most commercial insurance plans and Medicare Part D plans cover Lumakras, but coverage varies by formulary tier. Insurers typically prefer generic Sotorasib (Tier 1, lowest copay) over brand-name Lumakras (Tier 2-3, higher copay). Some plans require prior authorization or step therapy. Check your plan's formulary or call the number on your insurance card to confirm.
Several options for cash-pay patients: (1) Manufacturer patient assistance programs — the manufacturer may offer copay cards or free-drug programs for income-qualified patients; (2) Discount programs like GoodRx, SingleCare, or RxSaver typically save 20-80% off the cash price; (3) Mark Cuban's Cost Plus Drugs offers transparent generic pricing if a generic is available; (4) 340B-eligible community health centers offer drugs at federally negotiated discounts. Switching to generic Sotorasib is the single biggest cost reducer if your prescriber is open to it.
Brand-name Lumakras costs more than generic Sotorasib primarily for marketing reasons — patients can request the brand from their doctor even when a chemically identical generic exists. The active ingredient and clinical effect are the same.
Yes, a generic version of Lumakras (Sotorasib) is available. Generic medications typically cost 80-95% less than brand-name drugs. Ask your pharmacist about generic Sotorasib.
Medicare Part D spent $234.0M on Lumakras, covering 2,100 beneficiaries across 18,000 claims. This makes it one of the tracked drugs in the Medicare spending dashboard.
Ask your pharmacist about generic Sotorasib, which is typically much cheaper. You can also compare prices at different pharmacies, use prescription discount programs (GoodRx, SingleCare, Cost Plus Drugs), or ask your doctor about therapeutic alternatives in the same drug class.
The this entity record above pulls directly from CMS Medicare Part D Drug Spending data. What follows is the per-entity context — how this entity sits in the broader U.S. Medicare prescription-drug pricing distribution and which underlying factors drive the headline numbers.
The methodology behind every numeric value on this page is publicly documented on the CMS Medicare Part D Drug Spending data portal and described in detail on this site’s methodology page. Refresh cadence varies by underlying series; the page surfaces the as-of date for each number so readers can trace any figure back to the source release.
For readers using this page as a decision input, the related-entity pages elsewhere on the site provide the comparison set. The most useful comparison for this entity is typically a peer within U.S. prescription drugs with similar size, similar exposure, or similar geography — not the national-level summary alone.
Related
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims.